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Action of Hydralazine on Glucose Turnover and 
Plasma Lipids in Dogs 
By SHAFEEK S. SANBAR AND SILVIA A. D. DE ROMERO 
Acute effects of a single intravenous in- 
jection of hydralazine (20 mg./Kg.) on 
heart rate, femoral arterial blood pres- 
sure, glucose turnover (technique of 
priming injection-continuous infusion of 
glucose-U-C”) and plasma lipids and 
catecholamines were studied in 15 anes- 
thetized dogs. In 6 of the dogs, 3 re- 
ceived isotonic saline solution and 3 
received hydralazine diluent. These con- 
trol dogs had no changes in heart rate, 
arterial pressure or levels of plasma glu- 
cose and FFA. In the others, hydrala- 
zine produced significant, prompt and 
sustained increments in plasma FFA and 
heart rate and a decrement in diastolic 
(no change in systolic) blood pressure, 
the respective mean maximal changes 
from control levels being 330 Eq./L., 
57 x/min., and 26 mm.Hg. Plasma level 
and rate of appearance (hepatic output) 
of glucose increased after hydralazine, 
with a maximum increase in plasma glu- 
cose of 58 mg. % above control 2% 
hours after injection. Rate of disappear- 
ance (tissue uptake) of glucose remained 
unaltered despite the hyperglycemia. In 
3 dogs, high inferior vena cava blood 
showed marked increases above control 
levels of both plasma epinephrine and 
norepinephrine after hydralazine. Plas- 
ma cholesterol and triglyceride levels 
did not change. In conclusion, hydrala- 
zine induces hyperglycemia by increas- 
ing rate of appearance and by relatively 
inhibiting rate of disappearance of glu- 
cose. The changes in glucose turnover 
and the noted elevations in plasma FFA 
and heart rate are paralleled by in- 
creased secretion of catecholamines. 
(Metabolism 18: No. 4, April, 292-299, 
1969) 
H YDRALAZINE ( Apresoline; 1-Hydrazinophthalazine hydrochloride) is an antihypertensive drug which possesses both a central and a peripheral 
mechanism of acti0n.l It produces tachycardia and increases the cardiac output 
which, according to Moyer and Brest,l suggest centrally mediated sympatho- 
mimetic activity. Indeed, the drug is ineffective when the vasomotor center is 
severed from the spinal cord of animals,2 and its cardiostimulatory effect is in- 
hibited by surgical sympathectomy and by the ganglioplegic drug, hexameth- 
onium. 1 It is well established that hydralazine produces a number of side 
effects, including gastro-intestinal, cardiac, hematologic, immunologic, skin 
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and nervous system manifestations .ls3 On the other hand, very little is known 
about the metabolic effects of this drug. Esplugues-Requena and co-workers4 
reported that administration of hydralazine (about 15 mg./Kg. ) in dogs in- 
duces after 30 minutes from IO.7 to 78.5 per cent increase in carotid arterial 
blood sugar above initial values, and that a second dose of the drug elicited an 
even greater hyperglycemia. The authors found no histologic changes in the 
pancreas at autopsy. Since hydralazine administration appears to stimulate 
the sympathetic nervous system, it is possible that this drug may secondarily 
exert an effect on the metabolism of carbohydrates and lipids. 
The purpose of this investigation in anesthetized dogs is to delineate the 
effect of intravenous administration of hydralazine on glucose turnover, using 
an isotope-dilution technique, and on plasma free fatty acid ( FFA) , cholesterol, 
triglyceride, epinephrine and norepinephrine concentrations; systolic, mean 
and diastolic arterial blood pressure and pulse are also recorded. 
MATERIALS AND MEIXODS 
Fifteen male and female mongrel dogs weighing 11 to 16 Kg. were used in this study. 
Afer an overnight fast, the dogs were anesthetized with pentobarbital sodium (30 mg./Kg. 
body weight). A medium-size catheter (Intracath, D. R. Bard, Inc., Murray Hill, N.J.) 
was inserted in the cephalic vein for intravenous infusions and a polyethylene tube in the 
femoral artery for repeated blood sampling. The experimental procedures lasted 3 to 
4 hours. 
After a control period of !1 to 1 hour, 3 dogs received intravenously isotonic saline 
solution ( 1 ml/Kg. ), 3 received hydralazine diluent ( 1 ml/Kg. ), and 9 received hydra- 
lazine (30 mg. Apresoline in 1 ml. diluent/Kg. ); the injection was given over a period of 
about 3 minutes. In 5 of the latter 9 dogs, each serving as its own control, the technic 
of priming injection-continuous intravenous infusion of tracer glucose-U-Cl4 5 was utilized to 
determine the immediate changes in rates of appearance (Ra) and disappearance (Rd) of 
glucose following intravenous administration of hydralazine. The dose of tracer, calcula- 
tions of Ra and Rd and laboratory methods were identical to those reported in this journal.6 
Systolic, diastolic and mean femoral arterial pressure were recorded continuously on a 
Polygraph ( Model M8PM Gilson Medical Electronics, Middleton, Wis. ). Beside glucose, 
plasma was analyzed also for FFA,? cholesterol,* triglyceride9 and catecholamines, the 
latter measured by the trihydroxyindole technique of Lund10 as modified by Crout’l and 
von Euler and Lishajko.12 
RESULTS 
Intravenous injection of isotonic saline solution in 3 dogs (Fig. 1) produced 
no significant changes in systolic, mean and diastolic blood pressure, pulse, 
plasma glucose or FFA concentration during the four hour procedure. 
Intravenous injection of hydralazine ( Apresoline) diluent in 3 dogs (Fig. 2) 
produced a slight and gradual increase in systolic and mean blood pressure, but 
no changes in diastolic blood pressure, pulse, plasma glucose or FFA concen- 
tration. 
In contrast, injection of Apresoline in 9 dogs (Fig. 3) did not alter signifi- 
cantly the systolic blood pressure, but it decreased the mean and diastolic 
blood pressure and increased the pulse throughout the remainder of the pro- 
cedures. Plasma glucose concentration gradually increased to a maximum of 
58 mg. per cent above mean control levels at the end of the procedure. Plasma 
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Fig. L-Mean + S.E.M. 
changes in systolic, mean and 
diastolic arterial pressure, pulse, 
and plasma glucose and FFA 
concentration following saline 
administration in 3 dogs. 
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changes in systolic, mean and 
diastolic arterial pressure, pulse, 
and plasma glucose and FFA 
following administration of hy- 
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FFA concentration almost tripled within 30 minutes after injection of the drug, 
and it remained elevated until the end of the experiment. In 5 of the 9 dogs 
( Fig. 4)) plasma cholesterol and triglyceride concentrations remained unaltered 
following hydralazine administration. In these same dogs, the drug produced an 
increase in rate of appearance (Ra) but no change in rate of disappearance 
(Rd) of glucose (Table 1); the difference between Ra and Rd accounted for 
the gradual rise in plasma glucose concentration, 
In 3 of the 9 dogs which received Apresoline, plasma catecholamines were 
measured in blood obtained from the thoracic portion of the inferior vena cava 
at time 0,60 and 150 minutes. As shown in Table 2, both the concentrations of 
plasma epinephrine and norepinephrine were increased after drug injection 
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Fig. X-Mean i S.E.M. 
changes in systolic, mean and 
diastolic arterial pressure, pulse, 
and plasma glucose and FFA 
following hydralazine (Apreso- 
line) administration in dogs. 
ml” -10 0 30 60 90 120 150 
above control values; the values at 150 minutes were higher than at 60 minutes, 
which corresponded with the change in plasma glucose concentrations. 
DISCUSSION 
These studies in dogs confirm the hyperglycemic effect of large intravenous 
doses of hydralazine ( Apresoline ) , reported previously by Esplugues-Requena 
et al4 It is noteworthy that the hyperglycemia induced by hydralazine is 
gradual, reaching a maximum at the end of the procedure, 2% hours after intra- 
venous administration of the drug. It has also been determined isotopically that 
hydralazine hyperglycemia is associated with a slight increase in rate of ap- 
pearance of glucose, which represents primarily hepatic glucose output.13 
Furthermore, the rate of disappearance or tissue uptake of glucose remained 
unaltered despite a substantial hyperglycemia, the mean maximal increase in 
plasma glucose being 58 mg. per cent. These data indicate, therefore, that both 
an increment in Ra and a relative inhibition of Rd contributed to the produc- 
tion of hydralazine hyperglycemia. 
The data demonstrate further that hydralazine decreases the diastolic arterial 
pressure and markedly increase the pulse, plasma FFA and catecholamine 
concentrations. In view of these findings, it is conceivable that the reduction in 
blood pressure might have triggered the adrenal gland to increase its secretion 
of catecholamines which in turn influenced the pulse and plasma glucose and 
FFA metabolism. Such an adrenergic mechanism has been shown to play a 
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Fig. 4.-Mean (k S.E.M.) 
changes in pulse and concentra- 
tions of plasma glucose, FFA, 
triglyceride and cholesterol fol- 
lowing hydralazine (Apresoline) 
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role in the metabolic effects of hypotension induced by hemorrhage14-I5 and 
by the nondiuretic, benzothiadiazine derivative, diazoxide.16-la Similar met- 
abolic changes have also been reported in association with hypotension induced 
by sodium nitroprusside, lo trimethaphan camphorsulfonate ( Arfonad) and 
phenoxybenzamine ( Dibenzyline ) lo and large doses of diphenylhydantoin 
(Dilantin) in dogsTo 
However, it is also possible that the metabolic effects of hydralazine are 
mediated by direct stimulation of the sympathetic nervous system centrally. 
As mentioned earlier, the tachycardia induced by hydralazine is inhibited by 
surgical sympathectomy and by hexameth0nium.l Furthermore, Gupta and 
Bhargava21 have shown that local application of hydralazine over the floor of 
the fourth ventricle produces tachycardia, that after an intracerebroventricular 
injection of the drug tachycardia appears prior to hypotension, and that the 
tachycardia is not prevented by carotid sinus denervation. These data indicate 
a central site of action of the drug with respect to the tachycardia and hypo- 
tension, And it is conceivable that the effects of hydralazine on glucose and 
FFA metabolism may also be in part centrally mediated. This central nervous 
system component may act in a manner similar to that of epinephrine by 
stimulating the so-called “hyperglycemic center” which is situated in the floor 
of the fourth ventricle, as reviewed recently.22 
Finally, two other mechanisms should be considered in the action of hy- 
dralazine on glucose turnover and plasma FFA concentration. Firstly, the drug 
itself may possess direct actions on hepatic glucose output, tissue utilization of 
glucose or adipose tissue lipolysis. Secondly, the alterations in glucose turnover 
may be secondary to inhibition of insulin secretion by catecholamines23-25 as 
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Table 2.-Plasma Catecbolamines and Glucose Before and After HydraIazine Injection 
Plasma 
Dog No. D&~tilX3tiOlI 
Before After Hydralazine 
InjelFn 60’ 150’ 
1 Epinephrine (pg./L.) 0.001 0.425 0.550 
Norepinephrine (pg./L. ) 0.306 0.798 1.044 
Glucose (mg. % ) 67. 79. 81. 
2 Epinephrine 0.199 0.260 0.571 
Norepinephrine 0.181 0.373 0.488 
Glucose 86. 92. 98. 
3 Epinephrine 0.490 3.048 8.790 
Norepinephrine 0.203 1.055 1.463 
Glucose 84. 136. 212. 
~_ 
itself may directly inhibit insulin secretion. More studies in vivo and in vitro 
will be required to further elucidate the role that these factors play in the 
metabolic effects of hydralazine. 
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